Business Acquisition Bus acquisition - Table of acquired Intangibles (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Acquisition Related Costs		$ 3,200,000
Revenues	380,585,000	314,027,000	245,535,000
Net Income (Loss) Available to Common Stockholders, Basic	23,979,000	16,178,000	10,389,000
Trade Names [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Trade Names [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years
Customer Relationships [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Customer Relationships [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	30 years
Acquired Technology [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Acquired Technology [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
MTS-Medication Technologies [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Asset, Amount		83,900,000
Expected amortization of acquired intangibles first year		3,604,000
Weighted average life of intangibles	25 years 1 month 21 days
Revenues		47,200,000
MTS-Medication Technologies [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average life of intangibles	12 years
MTS-Medication Technologies [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average life of intangibles	30 years
MTS-Medication Technologies [Member] | Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Asset, Amount		6,800,000
Finite-Lived Intangible Asset, Useful Life	12 years
Expected amortization of acquired intangibles first year		567,000
MTS-Medication Technologies [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Asset, Amount		50,500,000
Expected amortization of acquired intangibles first year		1,707,000
MTS-Medication Technologies [Member] | Customer Relationships [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	28 years
MTS-Medication Technologies [Member] | Customer Relationships [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	30 years
MTS-Medication Technologies [Member] | Acquired Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Asset, Amount		26,600,000
Finite-Lived Intangible Asset, Useful Life	20 years
Expected amortization of acquired intangibles first year		1,330,000
Non-acute care solutions [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Revenues	95,919,000	53,867,000
Non-acute care solutions [Member] | MTS-Medication Technologies [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Net Income (Loss) Available to Common Stockholders, Basic		$ 2,900,000